Holen Sie sich die Stockscreener-App
5.08
4.87%
-0.26
Schlusskurs vom Vortag:
$5.34
Offen:
$4.97
24-Stunden-Volumen:
88,250
Relative Volume:
0.45
Marktkapitalisierung:
$3.71M
Einnahmen:
$2,000
Nettoeinkommen (Verlust:
$-12.72M
KGV:
-0.0707
EPS:
-71.8121
Netto-Cashflow:
$-3.91M
1W Leistung:
+1.40%
1M Leistung:
+2.83%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$4.97
$5.58
1-Wochen-Bereich:
$4.661
$6.47
52-Wochen-Spanne:
$3.38
$7.56
Nexentis Technologies Inc Stock (NXTS) Company Profile
Firmenname
Nexentis Technologies Inc
Sektor
Branche
Telefon
972544561349
Adresse
156 FIFTH AVENUE 10TH FLOOR, NEW YORK
Compare NXTS vs CTVA, NTR, CF, MOS, ICL
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NXTS
Nexentis Technologies Inc
|
5.08 | 3.71M | 2,000 | -12.72M | -3.91M | -71.81 |
CTVA
Corteva Inc
|
78.59 | 52.56B | 17.89B | 1.26B | 2.05B | 1.7029 |
NTR
Nutrien Ltd
|
62.86 | 30.17B | 27.83B | 2.42B | 2.21B | 4.9113 |
CF
Cf Industries Holdings Inc
|
102.93 | 15.81B | 7.41B | 2.12B | 1.62B | 11.13 |
MOS
Mosaic Company
|
22.90 | 7.28B | 12.05B | 575.40M | -534.60M | 1.6871 |
ICL
Icl Group Ltd
|
5.14 | 6.63B | 7.41B | 314.00M | 220.88M | 0.202 |
Nexentis Technologies Inc Aktie (NXTS) Neueste Nachrichten
Which stocks have an unusual volume on Wednesday? - ChartMill
Nexentis Shares Swing After Subsidiary Reaches Drug Discovery Research Milestone - Yahoo Finance
Nexentis subsidiary completes analysis of transport proteins - Investing.com
Nexentis stock choppy after subsidiary research milestone By Investing.com - Investing.com South Africa
Nexentis Technologies Inc. Subsidiary MitoCareX Bio Ltd. Completes Structural Analysis of SLC Transport Proteins to Enhance Drug Discovery Efforts - Quiver Quantitative
Nexentis Technologies (NXTS) sells 311,876 shares; concurrent warrants issued - Stock Titan
NXTS Q2 2025 Earnings: Loss Deepens as Pre‑Revenue Phase ContinuesGrowth Acceleration Report - newsline.com
Nexentis Technologies Announces New Equity Financing Agreements - TipRanks
Nexentis Technologies Raises $1.25 Million in Registered Direct Offering, Issues 5-Year Warrants - TradingView
Nexentis Technologies (NXTS) prices $1.25M stock and warrant offerings - Stock Titan
NXTS Q2 2025 Earnings: Loss Per Share of -$0.18 Amidst Limited Financial DisclosureRevenue Estimate Trend - newsline.com
Nexentis Technologies Inc. (NXTS) Surges 10.69% as Bullish Momentum BuildsVolatility Surface - newsline.com
NXTS Q2 2025 Earnings: Loss Per Share Widens but Stock Surges on Strategic ProgressHealthcare Earnings Report - newsline.com
NXTS News | NEXENTIS TECHNOLOGIES INC (NASDAQ:NXTS) - ChartMill
NXTS Q2 2025 Earnings: Net Loss of -$0.18 Per Share Triggers Double-Digit Stock DeclineEPS Surprise History - newsline.com
Nexentis Technologies (NXTS) Earnings Date and Reports 2026 - MarketBeat
NXTS Q2 2025 Earnings: EPS Loss Narrows, Stock Surges on Operational ProgressHealthcare Earnings Report - The Legal Advocate
Nexentis Technologies (NXTS) Surges 5.1%: Key Levels and Volume Patterns Signal Potential BreakoutCalendar Spread Trade - The Legal Advocate
Nexentis Expands Credit Facility Under Amended Financing Agreement - TipRanks
Nexentis Technologies Inc. Approves Amendment to A Facility Agreement - marketscreener.com
Nexentis Technologies (NASDAQ: NXTS) expands EUR 10M credit line and warrant terms - Stock Titan
Nexentis Technologies (NXTS) Surges 15.4% – Momentum Builds Above Key SupportAAII Bullish - newsline.com
Nexentis Technologies (NXTS) Gains 1.36% as Stock Tests Key Resistance Near $4.70Low Beta Factor - thelegaladvocate.com
Nexentis Technologies (NXTS) Earnings Outlook: Key Metrics for Q2 2025Retail Trader Picks - Newser
Nexentis subsidiary achieves drug discovery milestone By Investing.com - Investing.com South Africa
Nexentis Technologies says MitoCareX Bio achieves drug discovery milestone - TipRanks
Nexentis subsidiary reaches drug discovery milestone By Investing.com - Investing.com Nigeria
Nexentis subsidiary reaches drug discovery milestone - Investing.com
Nexentis subsidiary achieves drug discovery milestone - Investing.com
Nexentis develops new molecule to potentially tackle hard-to-treat cancers - Stock Titan
Nexentis Technologies (NASDAQ: NXTS) posts Q1 2026 loss, flags going concern risk - Stock Titan
Nexentis Technologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Nexentis Technologies Inc. Announces Drug Discovery Milestone Achieved by MitoCareX Utilizing MITOLINE® Platform - Quiver Quantitative
Nexentis Technologies Announces Optimization of Hit - GlobeNewswire
Nexentis Technologies Inc. (NXTS) - Zacks Investment Research
Number of shareholders of Nexentis Technologies Inc. – NASDAQ:NXTS - TradingView
Nexentis Technologies Secures US Trademark Approval for MitoCareX Algorithm Platform MITOLINE - ChemAnalyst
Nexentis Technologies stock jumps on trademark approval - Investing.com
Nexentis subsidiary receives U.S. trademark for drug platform By Investing.com - Investing.com South Africa
Nexentis Technologies stock jumps on trademark approval By Investing.com - Investing.com Nigeria
Nexentis subsidiary receives U.S. trademark for drug platform - Investing.com
Drug discovery firm secures U.S. trademark for its MITOLINE platform - Stock Titan
Nexentis Technologies Announces U.S. Trademark Registration - GlobeNewswire
NXTS (Nexentis Technologies) falls 2.62% after Q2 2025 earnings with no consensus performance benchmarks available.FCF Yield - newser.com
Nexentis Shareholders Approve Reverse Split and Financing Flexibility - The Globe and Mail
Shareholders back Nexentis (NITO) reverse split and equity financing plans - Stock Titan
[EFFECT] Nexentis Technologies Inc. SEC Filing - Stock Titan
Finanzdaten der Nexentis Technologies Inc-Aktie (NXTS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.32%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):